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Introduction
The analysis of the Cardiac Arrhythmia Suppression Ž . Trials CAST-I and CAST-II prompted the reconsideration of prophylactic antiarrhythmic treatment after myocardial infarction. The results shed light on the controversy that Class IrC type Na q channel blockers, i.e. flecainide and encainide, increased mortality in survivors of myocardial infarction despite their ability to reduce the number of Ž premature ventricular beats The Cardiac Arrhythmia Sup-Ž . pression Trial CAST Investigators, 1989; The Cardiac . Arrhythmia Suppression Trial II Investigators, 1992 . The results of these trials and those of the ESVEM and CAS-CADE trials shifted the attention to cardiac K q channel Ž blockers Mason, 1993; The CASCADE Investigators, . 1993 .
As a disappointment, in the SWORD trial D-sotalol, a so-called 'pure' Class III antiarrhythmic drug, which is known to block cardiac K q channels selectively, was shown to increase mortality in subsets of patients with Ž myocardial infarction and lowered ejection fraction Waldo . et al., 1996 . Accordingly, special attention has been paid to antiarrhythmic drugs with complex effects on different ion Ž channels and receptors. These include D,L-sotalol a delayed rectifier K q channel blocker and b-adrenoceptor . Ž q antagonist and amiodarone a K channel blocker possessing Na q and Ca 2q channel blocking properties and . antiadrenergic activity . Amiodarone has been shown to exert a strong antiarrhythmic effect in a number of studies and is currently considered to be one of the most efficacous antiarrhythmic drugs available in clinical practice. Long-term treatment with amiodarone, however, leads to Ž the development of serious extracardiac side effects Hille-. man et al., 1998 . Therefore, it seems worthwhile to pursue the development of novel amiodarone-like compounds with marked antiarrhythmic potency but without unwanted extracardiac side effects. Fig. 1 is a novel N-phenoxyal-. kyl -N-phenylalkylamine that has been developed recently. Although it is not an amiodarone congener, based on its chemical structure, the compound is expected to show amiodarone-like electrophysiological effects, i.e. both Class IrB and Class III properties.
In the present study, we investigated the effect of GYKI-16638 and D-sotalol on the incidence of coronary artery occlusion and reperfusion-induced arrhythmias in anaesthetized rabbits. We also studied the cellular electrophysiological effects of GYKI-16638 in rabbit right ventricular papillary muscle and in rabbit single isolated ventricular myocytes.
Materials and methods

Animals
Male rabbits weighing 2-3 kg were used for the experiments. The animals were allowed to have tap water and Ž . laboratory rabbit chow Altromin, Godollo, Hungary ad¨l ibitum until the experiment. The animal handling protocol was reviewed and approved by the Ethics Committee for the Protection of Animals in Research of the Faculty of Medicine, University of Szeged, Szeged, Hungary.
Coronary artery ligation and reperfusion
The animals were anaesthetized with 30 mgrkg pentobarbitone-Na given intravenously in a volume of 1 mlrkg into the marginal vein of the right ear. Acute coronary artery occlusion and reperfusion were performed as de-Ž . scribed by Coker 1989 . To measure blood pressure, a catheter filled with isotonic saline containing 500 IUrml Ž . heparin the animals were not heparinized was introduced into the right carotid artery. The catheter was connected to Ž a pressure transducer Gould-Statham, P23ID, Hugo Sachs . Electronik, March-Hugstetten, Germany and blood pres-Ž sure was recorded on an oscillographic recorder Watanabe, . WTR 331, Hugo Sachs Electronik . For the infusion of drugs, another catheter was introduced into the marginal vein of the left ear.
After tracheal cannulation, thoracotomy was performed in the fourth intercostal space and artificial ventilation was Ž started with room air Harvard rodent ventilator, model . 683, Harvard Apparatus, South Natick, MA, USA , with respiratory volume and rate subsequently adjusted to keep Ž blood gases and pH within the normal range 7 mlrkgr . stroke, 40 strokesrmin, respectively . Following pericar-Ž diotomy, a loose loop of 4-0 atraumatic silk Ethicon, . Edinburgh, UK was placed around the first branch of the left circumflex coronary artery just under its origin. Both ends of the ligature were led out of the thoracic cavity through a flexible tube.
After stabilization of blood pressure and heart rate Ž . approximately 10 min , saline or 0.03 or 0.1 mgrkg GYKI-16638 or 1 or 3 mgrkg D-sotalol was administered i.v. during a 1-min infusion in a volume of 2 mlrkg, 5 min prior to coronary artery occlusion.
Coronary artery occlusion and, thus, local myocardial ischaemia, was produced by tightening the loose loop and clamping on the silk. After 10 min of coronary artery occlusion, the ligature was released to permit reperfusion for 10 min.
Ž . The electrocardiogram lead I, II, III was registered Ž using a thermographic recorder ESC 110 4 CH, Multiline, . Esztergom, Hungary with subcutaneous needle electrodes. QT interval was defined as the time between the first deviation from the isoelectric line during the PR interval until the end of the TU wave. QT interval corrected for Ž . heart rate QT was calculated using the following equa- Arrhythmias were detected and diagnosed in accordance with the Lambeth conventions as ventricular tachycardia, ventricular fibrillation and other types of arrhythmias, including single extrasystoles, bigeminy, salvos and brady-Ž . cardia Walker et al., 1988 . Ž At the end of the experiment, heparin-Na 500 IUrkg, . i.v. was administered and the animals were killed. The hearts were cut out from the chest in order to determine the size of the occluded zone. After the ligation was ( )tightened, the hearts were retrogradely perfused via the aorta with 20 ml saline and 10 ml of 96% ethanol as Ž . previously described by Lepran et al. 1983 . The non-de-Ž . naturated area occluded zone was excised and its extent is expressed as a percentage of the total wet weight of the ventricles. Four animals with an occluded zone less than 16% or larger than 32% were excluded from the final evaluation.
Drug administration protocol
Ž . D-Sotalol 1 or 3 mgrkg was dissolved in saline, and Ž . GYKI-16638 0.03 or 0.1 mgrkg was dissolved in propylene glycolrsaline, 1:1 mixture. Both drugs were applied 5 min prior to coronary artery ligation in a volume of 2 mlrkg. Each dose was prepared on the day of the experiment. Control animals received propylene glycolrsaline, 1:1 mixture in a volume of 2 mlrkg.
Measurement of action potential parameters in rabbit right Õentricular papillary muscle
Following cervical dislocation, the heart of each animal was rapidly removed through a right lateral thoracotomy. The hearts were immediately rinsed in oxygenated Tyrode's Ž . solution containing in mM : NaCl, 115; KCl, 4; CaCl , ventricle were individually mounted in a tissue chamber Ž . volumef 50 ml . Each preparation was initially stimu-Ž w x lated HSE Hugo Sachs Electronik stimulator type 215rII, . March-Hugstetten, Germany at a basic cycle length of 500 Ž . ms frequencys 2 Hz , using 2-ms long rectangular constant voltage pulses isolated from ground and delivered across bipolar platinum electrodes in contact with the preparation. We applied the following types of stimulation in the course of the experiments: stimulation with a con-Ž . stant cycle length of 500 ms 2 Hz ; stimulation with different constant cycle lengths ranging from 300 to 5000 ms taking the measurement after the 25th beat.
To determine the recovery of V , extra test action max Ž . potentials were elicited using single test pulses S in a 2 preparation driven at a basic cycle length of 500 ms. The S -S coupling interval was increased progressively from 1 2 the end of the effective refractory period up to 10 s. The time constant for recovery of V was fitted to a single max exponential function, starting at the 40 ms diastolic interval and ending at 5 s. Before the control measurement, at least 1 h was allowed for each preparation to equilibrate while being continuously superfused with Tyrode's solution. The temperature of the superfusate was kept constant at 378C. Transmembrane potentials were recorded using a conventional microelectrode technique. Microelectrodes filled with 3 M KCl and having tip resistances of 5-20 m V were connected to the input of a high impedance electrometer Ž . HSE microelectrode amplifier type 309 , which was referenced to the ground. The first derivative of transmembrane Ž . potentials V was electronically derived by an HSE max Ž . differentiator type 309 . The voltage outputs from all amplifiers were displayed on a dual-beam memory oscillo-Ž scope Tektronix 2230 100 MHz digital storage oscillo-. scope, Beaverton, OR .
Ž . The maximum diastolic potential MDP , action poten-Ž . tial amplitude APA , and action potential duration mea-Ž . sured at 50% and 90% repolarization APD were 50 -90 obtained using software developed in our department Ž . HSE-APES . GYKI-16638 was dissolved in dimethyl sul-Ž . foxide DMSO as a 1-mM stock solution. After the control measurements, GYKI-16638 was added to the tissue bath to obtain a final concentration of 2 mM and the measurements were repeated after a 30-min incubation time.
To select the single in vitro concentration, we were guided by pharmacokinetic studies with GYKI-16638. In these measurements, the obtained plasma concentration after GYKI-16638 administration correlated well with the concentration used in our in vitro studies with GYKI-16638.
Whole-cell configuration of the patch-clamp technique
Single ventricular myocytes were obtained by enzy-Ž . matic dissociation from New Zealand rabbits 1-2 kg by Ž . a technique described earlier in detail Varro et al., 1996 .
One drop of cell suspension was placed in a transparent recording chamber mounted on the stage of an inverted Ž . microscope TMS; Nikon, Tokyo, Japan , and at least 5 min were allowed for individual myocytes to settle and adhere to the bottom of the chamber before superfusion was started. Myocytes that were used were rod-shaped with clear striations. HEPES-buffered Tyrode solution served as the normal superfusate in all experiments. This Ž . solution contained mM : NaCl 144, NaH PO 0.33, KCl configuration of the patch-clamp technique. After a high Ž . 1-10 GV resistance seal was established by gentle suction, the cell membrane beneath the tip of the electrode was disrupted by further suction or by application of 1.5 V electrical pulses applied for 1-5 ms. Series resistance was Ž typically 4-8 M V prior to compensation 50-80%, de-. pending on the voltage protocol utilized . Experiments, where the series resistance was high, or where it increased substantially during measurement, were terminated and the data were discarded. Membrane currents were digitized Ž using a 333-kHz analog-to-digital converter Digidata 1200, . Ž Axon Instruments under software control pClamp 6.0, . Axon Instruments . Analyses were performed using Axon Ž . pClamp 6.0 software after low-pass filtering at 1 kHz. All patch-clamp data were collected at 378C.
GYKI-16638 was diluted at the time of use from a 10-mM stock solution containing 100% DMSO. DMSO at Ž . the resulting concentrations 0.2% produced no discernible effect on APD or the membrane currents assessed. All stock solutions were prepared using HEPES-buffered Tyrode solution as the solvent.
Statistical eÕaluation
For the evaluation of data obtained from the cellular electrophysiology experiments, Student's t-test for paired data was used. All data are expressed as means " standard Ž . error of the mean S.E.M. .
The incidence of arrhythmias was calculated and compared by using the x 2 method. All other variables are expressed as means " S.E.M. and, after analysis of variance, were compared by means of the modified t statistic Ž . of Wallenstein et al. 1980 . Differences were considered significant when P values were less than 0.05.
Results
Effect of GYKI-16638 on haemodynamic Õariables in anaesthetized rabbits
There were no significant differences between the mean arterial blood pressures of control and D-sotalol-or GYKI-16638-treated animals. Mean arterial blood pressure fell significantly in all groups due to coronary artery occlusion Ž as compared to preocclusion values 74 " 3.9 vs. 101 " 2.8 mm Hg, 78 " 4.5 vs. 97 " 3.2 mm Hg, 84 " 2.6 vs. 95 " 3.5 mm Hg, 69 " 3.8 vs. 93 " 3.4 mm Hg and 74 " 3.9 vs. 94 " 2.7 mm Hg in controls, 1 and 3 mgrkg D-sotalol-, 0.03 and 0.1 mgrkg GYKI-16638-treated ani-. mals, respectively, all P -0.05 .
The infusion of 1 and 3 mgrkg D-sotalol, as well as 0.03 and 0.1 mgrkg GYKI-16638, significantly decreased the heart rate of rabbits compared to the basal values Table 2 Effect of D-sotalol and GYKI-16638 on the incidence of arrhythmias during 10 min of coronary artery occlusion in anaesthetized rabbits Table 3 Effect of D-sotalol and GYKI-16638 on the incidence of arrhythmias during 10 min of reperfusion following 10 min of coronary occlusion in anaesthetized rabbits 
Effect of GYKI-16638 on QT and QT interÕals in c anaesthetized rabbits
D-Sotalol infusion, in the dose of 1 and 3 mgrkg, Ž . significantly lengthened QT and QT intervals Table 1 . c GYKI-16638, in the dose of 0.03 mgrkg, had no effect on QT and QT intervals, but caused a significant increase of 
Arrhythmias during 10 min of myocardial ischaemia
In all groups, arrhythmias did not develop either during the 1-min infusion of drugs or vehicle, or between the infusion of drugs and coronary occlusion. The incidence of arrhythmias in the control, D-sotaloland GYKI-16638-treated groups during 10 min of coronary artery occlusion is shown in Table 2 . The incidence of ventricular fibrillation was not statistically different in the D-sotalol-or GYKI-16638-treated animals compared to the control group.
There were no significant differences in the treated and control groups with respect to the incidence of other types of arrhythmias during 10 min of coronary artery ligation.
Reperfusion-induced arrhythmias
Arrhythmias induced by reperfusion appeared within 10-30 s following the release of the coronary artery ligature.
Ž . D-Sotalol 1 and 3 mgrkg and 0.03 mgrkg GYKI-16638 pretreatment significantly reduced the incidence of Ž . reperfusion-induced ventricular fibrillation Table 3 . All drug pretreatments significantly increased the number of Ž animals surviving reperfusion 75% and 83% with 1 and 3 mgrkg D-sotalol, 82% and 77% with 0.03 and 0.1 mgrkg . GYKI-16638 vs. 18% in controls, P -0.05, respectively .
The number of animals that did not develop any arrhythmia during reperfusion was significantly higher in the Table 4 The effect of 2 mM GYKI-16638 on the action potential parameters in rabbit right ventricular papillary muscle shown as insets.
( )Ž . 0.1 mgrkg GYKI-16638-treated group Table 3 . There were no differences in the incidence of other types of arrhythmias between the animals receiving pretreatment Ž . and control rabbits during reperfusion Table 3 .
Effect of GYKI-16638 on the action potentials in rabbit papillary muscle
The effect of 2 mM GYKI-16638 on the action potentials at 2 Hz stimulation frequency in rabbit right ventricular papillary muscle is shown in Fig. 2 use-dependent and became significant only at stimulation Ž . cycle lengths shorter than 700 ms Fig. 3 . This was consistent with a delayed recovery of V measured in the max Ž presence of the drug t -30 ms in controls, and 328.2 " Ž . . 65.0 ms, n s 4 with 2 mM GYKI-16638 . The APD prolongation induced by 2 mM GYKI-16638 was reverse use-dependent: the slower the stimulation frequency, the Ž . more pronounced the APD prolongation Fig. 3 . 
Effect of GYKI-16638 on Õarious transmembrane K q currents in isolated rabbit Õentricular myocytes
The effect of GYKI-16638 on various K q currents was Ž studied in isolated single rabbit ventricular myocytes Fig. . 4 . The rapid component of the delayed rectifier outward q Ž . K current I was elicited from y40 mV holding Kr potential to various 1-s long test pulses ranging from y20 to q50 mV and then returning back to y40 mV. The amplitude of the deactivating tail current at this potential was measured as the difference between the peak tail current and the holding current level and was attributed to Ž . I at q50 mV, it was 86.9 " 16.6 pA, n s 4 . Because Kr of the very slow deactivation of I , the pulsing frequency Kr in these experiments was 0.01 Hz. As Fig. 4A shows, 2 mM GYKI-16638 completely inhibited the I tail current.
Kr
Similar results were obtained in three other cells. Fig. 4B and C shows that 2 mM GYKI-16638 did not change or only minimally affected the transient outward Ž . The effect of 2 mM GYKI-16638 on the inward rectiq Ž . fier K current I was studied at a holding potential of k1 y80 mV and was elicited by 300-ms long voltage pulses to various potentials ranging from y140 to 0 mV. I was k1 determined as the steady-state current at the end of the voltage pulses. As a result of a representative experiment, Fig. 4D shows that 2 mM GYKI-16638 moderately decreased the amplitude of the steady state current-voltage relationship attributed to inhibition of I . This effect was k1 reversible upon 5 min of washout. The average value of Ž . the I current n s 7 at y100 mV before drug superfuk1 sion was y2648" 399 pA, which was significantly reduced to y2152" 401 pA after 5 min of superfusion with 2 mM GYKI-16638.
Discussion
The recently developed GYKI-16638 is a member of a Ž . new series of N-phenoxyalkyl -N-phenylalkylamine compounds. Its structure combines Class IrB and Class III structural elements, i.e. those of D-sotalol and mexiletine.
In the present study, the antiarrhythmic effect of GYKI-16638 in anaesthetized rabbits and its electrophysiological effects in rabbit right ventricular papillary muscle preparations were investigated. We compared the antiarrhythmic effect of GYKI-16638 to that of D-sotalol, a well-known pure Class III antiarrhythmic agent.
GYKI-16638 exerted an antiarrhythmic effect in our experiments that was comparable to that of D-sotalol. Both compounds significantly decreased the number of animals that died due to lethal ventricular arrhythmias during reperfusion after 10 min of regional myocardial ischaemia. The significant improvement of survival during reperfusion occurred in spite of the fact that there were animals that had reversible ventricular fibrillation in the control group as well. This is a well-known phenomenon in experimental arrhythmia studies, i.e. relatively small hearts can recover from ventricular fibrillation, while in human and large Ž animal hearts, this arrhythmia is irreversible Botting et al., . 1986 .
The antiarrhythmic activity of GYKI-16638 was already observed after the administration of the lower dose which did not influence QT and QT intervals. This may suggest c that GYKI-16638 has a mechanism of action that is based not solely on the prolongation of repolarization. Indeed, it was found that GYKI-16638 not only caused a significant increase in APD and, consequently, in the effective refractory period, but that it also significantly reduced the maxi-Ž . mum upstroke velocity V in rabbit right ventricular max q Ž . papillary muscles, reflecting its fast Na channel I Na blocking ability. However, it was found that, in a higher dose, it significantly prolonged the QT and QT intervals c in anaesthetized rabbits, as was expected from its in vitro effect on the APD. The Na q channel blocking effect was significant only at cycle lengths shorter than 700 ms. This was consistent with the measured time constant for recovery of V , which resembled that of Class IrB type drugs Campbell, 1983 and amiodarone Varro et al., 1985 . Such an effect may have therapeutic importance in the inhibition of arrhythmias due to early afterdepolarizations Ž . Papp et al., 1996 . D-Sotalol has been shown to exert an antiarrhythmic Ž effect in a number of animal Lynch et al., 1985; Usui et ( ). al., 1993; Hashimoto et al., 1995 and human studies Ž . Hohnloser et al., 1995; Koch et al., 1995 with a proposed Ž mechanism of action of terminating re-entry Fei and . Frame, 1996 . However, it was shown in the SWORD trial that D-sotalol increased mortality in patients with myocar-Ž . dial infarction Waldo et al., 1996 . The results shifted attention towards antiarrhythmic compounds with a combined mechanism of action. As an example, amiodarone, an antiarrhythmic agent with a complex mode of action, has attracted a great deal of interest recently. It has been shown to decrease ventricular fibrillation vulnerability in Ž rabbit hearts following long-term pretreatment Behrens et . al., 1997 , to be protective against ischaemia-and reperfu-Ž sion-induced arrhythmias Varro and Rabloczky, 1986; . Coker and Chess-Williams, 1991; Li and Northover, 1992 , and to be effective in the treatment of life-threatening Ž . ventricular arrhythmias in humans Singh, 1999 . Also, some multicenter clinical trials have shown that amiodarone may reduce the incidence of arrhythmia-related Ž . sudden death Julian et al., 1997; Cairns et al., 1997 . Several electrophysiological studies showed that amiodarone possessed both Class IrB and Class III antiarrhyth-Ž mic properties Singh and Vaughan Williams, 1970; Varró . et al., 1985; Honjo et al., 1991; Maruyama et al., 1995 , as 2q Ž . well as Ca channel blocking Nattel et al., 1987 and Ž . sympatholytic effects Polster and Broekhuysen, 1976 . While effectively diminishing the development of re-entry arrhythmias, selective I blockers can increase the inciKr dence of arrhythmias, by increasing the interventricular dispersion of repolarization and initiating early afterdepolarizations, leading to torsade de pointes tachycardia Ž . Verduyn et al., 1997; Hohnloser, 1997 . It was demonstrated that almokalant, a selective I blocker, signifiKr cantly reduced the incidence of coronary artery occlusionr reperfusion-induced arrhythmias but also showed marked Ž proarrhythmic activity Carlsson et al., 1993a; Farkas et . al., 1998 . D-Sotalol has also been shown to induce tor-Ž sades de pointes in animals Buchanan et al., 1993; Vos et . Ž . al., 1995 and humans Gottlieb et al., 1997 . Amiodarone was found to have a remarkably low potential for inducing torsades de pointes tachyarrhythmias de-Ž spite its ability to prolong the QT interval Hohnloser et c . al., 1994 . The decrease in the transmural dispersion of ventricular repolarization and the consequent inhibition of the development of early afterdepolarization can possibly Ž . explain this effect of amiodarone Sicouri et al., 1997 . Class IrB antiarrhythmics may reduce the occurrence of Ž this arrhythmia. Mexiletine Shimizu and Antzelevitch, . Ž . 1997 and lidocaine in both animal Carlsson et al., 1993b Ž . and human studies Assimes and Malcolm, 1998 were shown to suppress torsades de pointes induced by D-sotalol. Antiarrhythmic drugs with a Class IrB action have also been shown to be effective against coronary artery Ž occlusionrreperfusion-induced arrhythmias Bonaduce et al., 1986; Uematsu et al., 1986; He et al., 1992; Komori et . al., 1995 . Also, the combination of mexiletine and sotalol prevented ventricular tachycardia induced by programmed Ž stimulation in dogs with chronic infarction Chezalviel et . Ž . al., 1993 , and Luderitz et al. 1991 concluded in their review that in humans, the combination of mexiletine and sotalol suppressed both premature ventricular beats and complex ventricular arrhythmias more effectively than sotalol alone. These results suggest that an antiarrhythmic compound with combined Class III and Class IrB effects could reduce the incidence of re-entry arrhythmias without a high risk of inducing torsades de pointes arrhythmias.
The exact ionic mechanism of the electrophysiologic and antiarrhythmic effects of GYKI-16638 is not fully understood. As mentioned above, the use-dependent depression of V strongly argues for inhibition of the fast max inward Na q current. The APD lengthening effect of the compound can be best explained by the marked depression of I and, to a lesser extent, by the decrease of the I .
Kr k1
Therefore, based on the cellular electrophysiological measurements, GYKI-16638 can be regarded as an antiarrhyth-Ž mic compound which -like amiodarone Varro et al., . 1996; Kodama et al., 1997 -interferes with multiple transmembrane ion channels.
When administered chronically, amiodarone exhibits Ž serious extracardiac side effects that limit its use Hilleman . Ž et al., 1998 . GYKI-16638 shares some Class IrB q . Class III , but not all of the electrophysiological properties of amiodarone and its chemical structure is also different. Based on its different chemical structure, it can be reasonably expected that this compound, unlike amiodarone, will be relatively free of extracardiac side effects. Due to its Class IrB action, it is also expected that the compound will lack the significant inhibitory effect on conduction at a normal heart rate. The compound also showed reverse frequency-dependent prolongation of APD in rabbit papil-Ž . lary muscle Fig. 3 , an effect which resembles that of D-sotalol or any specific I blocker. Therefore, further Kr studies are needed to elucidate the possible side effects of GYKI-16638, including its capability to induce torsades de pointes or conduction disturbance-related arrhythmias.
The haemodynamic side effects of antiarrhythmic agents are of particular importance. GYKI-16638 did not change the mean arterial blood pressure, but decreased the heart rate of anaesthetized rabbits. We also found that the administration of D-sotalol significantly decreased heart rate in rabbits. A similar heart rate decreasing effect of D-sota-Ž . lol has been shown by Schwartz et al. 1987 , although this compound lacks the antiadrenergic properties of D,L-sotalol. A moderate decrease in heart rate may be beneficial, especially in the setting of myocardial ischaemia and Ž . reperfusion-induced arrhythmias Bernier et al., 1989 . In conclusion, we demonstrated that GYKI-16638, a novel antiarrhythmic drug candidate, protected against coronary artery occlusion and reperfusion-induced arrhythmias in anaesthetized rabbits. This protection was already noticed at a lower dose, which did not lengthen the QT c interval significantly. Based on the results of our cellular ( )electrophysiological investigations in rabbit right ventricular papillary muscle, it can be assumed that GYKI-16638 exerts its antiarrhythmic effect through combined Class IrB and Class III actions. 
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